Sirtuins as modifiers of Parkinson's disease pathology
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is the most common movement disorder associated with the elderly which, other than symptomatic therapies, has no effective treatment or preventive measures. Sirtuins and their pharmacological activators/inhibitors have been associated with a range of neuroprotective effects, and a large body of work on sirtuins' influence on PD pathology has accumulated over the past decade. Here, evidence for sirtuins' activities as modifiers of PD pathology and how the mammalian sirtuin paralogues may have conflicting impacts on PD pathogenesis and disease progression is reviewed. The possible cellular and molecular mechanisms underlying sirtuin activities in PD are discussed in the light of current knowledge with reference to autophagy, mitochondrial homeostasis, and microtubule dynamics. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Das, S., Mitrovsky, G., Vasanthi, H. R., & Das, D. K. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/345105 · Cited by 173
RetractedSirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., Sou, Y.-S., Saiki, S., Kawajiri, S., Sato, F., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910140 · Cited by 1,969 · cited 1×
“PINK1 detects mitochondrial damage, and its association with the mitochondrial membrane is stabilized by mitochondrial depolarization (Matsuda et al., 2010; Kondapalli et al., 2012).”
BackgroundCalorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Sirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868 · cited 2×
“Resveratrol is a known SIRT1 activator and has been shown to increase replicative life span in yeast (Howitz et al., 2003) and to mimic CR in animals (Wood et al., 2004) via Sir2/SIRT1 activation.”
BackgroundLin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775 · cited 2×
“The yeast Sir2p (mammalian SIRT1) and its orthologs have indeed been strongly implicated as key factors underlying the health improvement and longevity effect of caloric restriction (CR; Lin et al., 2000; Anderson et al., 2003; Cohen et al., 2004), a regime of reduced food intake that is known to extend health and lif…”
BackgroundSIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation
Hirschey, M. D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D. B., Grueter, C. A., Harris, C., Biddinger, S., Ilkayeva, O. R., et al. (2010) · Nature · doi:10.1038/nature08778 · Cited by 1,687
Price, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.003 · Cited by 1,602 · cited 1×
“In this regard, SIRT1 has been known to act in conjunction with the cAMPdependent kinase (Cant o et al., 2009, 2010; Price et al., 2012).”
BackgroundHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Cited by
Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders
Jęśko, H., Wencel, P., Strosznajder, R. P., & Strosznajder, J. B. (2017) · Neurochemical Research · doi:10.1007/s11064-016-2110-y · Cited by 259
Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons
Schwab, A. J., Sison, S. L., Meade, M. R., Broniowska, K. A., Corbett, J. A., & Ebert, A. D. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.010 · Cited by 80
“For example, increasing levels of SIRT1 or SIRT3 protect dopaminergic neurons from toxin-induced cell death (Tang, 2017).”
BackgroundSirtuins, a key regulator of ageing and age-related neurodegenerative diseases
Bhatt, V., & Tiwari, A. K. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2057849 · Cited by 28
Dhiman, S., Mannan, A., Taneja, A., Mohan, M., & Singh, T. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122537 · Cited by 25
Could sirtuin activities modify ALS onset and progression?
Tang, B. L. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0452-2 · Cited by 24
Self-citation
Metadata
- Authors
- Tang, B. L.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2016-07-12
- Volume
- 95
- Issue
- 4
- Pages
- 930-942
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2465314048
- Cited by
- 40
- References
- 44
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sirtuins as modifiers of Parkinson's disease pathology. https://app.cochat.ai/papers/10.1002/jnr.23806
- The paper
- Tang, B. L. (2017). Sirtuins as modifiers of Parkinson's disease pathology. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.23806
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.